

## **AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

### **LISTING OF CLAIMS:**

1.-10. (Canceled)

11. (Currently amended) ~~A pharmaceutical composition for A method for treatment of abnormal growth of a smooth muscle cell, said method comprising administering an effective amount of a polypeptide to a subject in need of such treatment, wherein said polypeptide comprises according to claim 1 or 2, in association with a pharmaceutically acceptable diluent and/or carrier;~~

(i) an amino acid sequence as shown in SEQ ID NO. 13 or 14, or  
(ii) an amino acid sequence which is at least 90% homologous to the amino acid sequence shown in SEQ ID NO. 13 or 14, or  
(iii) a fragment of (i) or (ii) where said fragment inhibits proliferation of smooth muscle cells.

12. (Currently amended) ~~A pharmaceutical composition for A method of treatment of arteriosclerosis, restenosis after PTCA, or myosarcoma, said method comprising administering a an effective amount of a polypeptide to a subject in need of such treatment, wherein said polypeptide comprises according to claim 1 or 2, in association with a pharmaceutically acceptable diluent and/or carrier;~~

(i) an amino acid sequence as shown in SEQ ID NO. 13 or 14, or  
(ii) an amino acid sequence which is at least 90% homologous to the amino acid sequence shown in SEQ ID NO. 13 or 14, or  
(iii) a fragment of (i) or (ii) where said fragment inhibits proliferation of smooth muscle cells.

13. (Currently amended) An in vitro screening method for an antagonist or agonist of the polypeptide according to claim 1 or 2, comprising;

a) contacting a cell with a test compound and said a polypeptide, said polypeptide comprising;

(i) an amino acid sequence as shown in SEQ ID NO. 13 or 14, or  
(ii) an amino acid sequence which is at least 90% homologous to the amino acid sequence shown in SEQ ID NO. 13 or 14, or  
(iii) a fragment of (i) or (ii) where said fragment inhibits proliferation of smooth muscle cells and a test compound,

b) determining a result on cell growth of said contact, and  
c) comparing said result with a second result from a control experiment, wherein said control experiment comprises contacting a cell-is contacted with the said polypeptide in the absence of the test compound, thereby identifying compounds that modulate the effects of said polypeptide on said cell.

14. (Canceled)

15. (Canceled)